Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
Naglaa S Elabd,1 Safaa I Tayel,2 Moamena S Elhamouly,1 Shaimaa A Hassanein,3 Samar M Kamaleldeen,4 Fatma E Ahmed,5 Mahmoud Rizk,6 Abdelnaser A Gadallah,7 Soma E Ajlan,8 Ahmed S Sief9 1Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 2Medical Biochemistry and M...
Guardado en:
Autores principales: | Elabd NS, Tayel SI, Elhamouly MS, Hassanein SA, Kamaleldeen SM, Ahmed FE, Rizk M, Gadallah AA, Ajlan SE, Sief AS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7ec437207865467b8d245a2264218463 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla M, et al.
Publicado: (2019) -
Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen M, et al.
Publicado: (2017) -
Viral Determinants of miR-122-Independent Hepatitis C Virus Replication
por: Sharon E. Hopcraft, et al.
Publicado: (2016) -
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Behnaz Amernia, et al.
Publicado: (2021) -
Population Pharmacokinetics of CC-122
por: Cheng Y, et al.
Publicado: (2021)